Efficacy and Safety of Antidepressant Drugs in Patients with Dementia
- Howard S. Kirshner
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Trial: Banerjee S, Hellier J, Dewey M, et al.: Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomized, multicentre, double-blind, placebo-controlled trial. Lancet 2011, 378:403–411.
Rating: •Of major importance.
Introduction: Management of the behavioral disorders associated with Alzheimer’s disease (AD) has been in considerable flux. Most patients with AD eventually develop behavioral symptoms such as depression, anxiety, and later, agitation, hallucinations, and delusional thinking. These symptoms are very distressing to families and often play a greater role in the inability of families to care for patients at home than do the cognitive deficits. Treatment with antipsychotic drugs, in particular, has been controversial, because of the risks of mortality, stroke, myocardial inf
- Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic treatment for dementia. Meta-analysis of randomized, placebo-controlled trials. JAMA. 2005;294:1934–43. CrossRef
- Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Ca Med Assoc J. 2007;176:627–32. CrossRef
- Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66:1090–6. CrossRef
- Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168:1090–6. CrossRef
- Kirshner HS. Controversies in behavioral neurology: the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. Current Neurol Neurosci Rep. 2008;8:471–4. CrossRef
- Schneider LS, Tariot PN, Dagerman PS, et al. for the CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–38. CrossRef
- Wang PS, Schneeweiss S, Avorn J. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Eng J Med. 2005;353:2335–41. CrossRef
- Dolder C, McKinsey J. Low-dose divalproex in agitated patients with Alzheimer’s disease. J Pschiatr Pract. 2010;16:63–7. CrossRef
- Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;8:CD003945.
- Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer’s disease. Arch Gen Psychiatry. 2011;68:853–61. CrossRef
- Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61.
- Sommer OH, Aga O, Cvancarova M, et al. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord. 2009;27:155–63. CrossRef
- Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s disease. Neurology. 2004;63:214–9.
- Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57–63. CrossRef
- Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942–52. CrossRef
- Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer’s disease. J Clin Psychiatry. 1994;55:536–8.
- Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271–8.
- Seitz DP, Adunuri N, Gill SS. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16:CD008191.
- Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–46. CrossRef
- Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18:332–40. CrossRef
- Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;49:577–85. CrossRef
- Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271–84. CrossRef
- Brodaty H. Antidepressant treatment in Alzheimer’s disease. Lancet. 2011;378:375–6. CrossRef
- Efficacy and Safety of Antidepressant Drugs in Patients with Dementia
Current Neurology and Neuroscience Reports
Volume 11, Issue 6 , pp 520-522
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Author Affiliations
- 1. Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA